四月份血液暨腫瘤科學術活動
Section
Meeting
時間: AM
地點: B2辦公室
|
日期 |
內容 |
負責醫師 |
||
|
4/4(W3) |
Prospective Multicentric Randomized Phase
III Study of Imatinib in Patients With Advanced GIST Comparing Interruption
Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group |
R4鄭弘毅/謝瑞坤主任 |
||
|
4/6(W5) |
Case discussion |
R1蔡菀庭/謝瑞坤主任 |
||
|
4/11(W3) |
Drug introduction~ VELCADE |
產品經理 /謝瑞坤主任 |
||
|
4/13(W5) |
A
Comparison of Allografting with Autografting for Newly Diagnosed Myeloma N Engl J Med 2007;356:1110-20. |
R1蔡秉昇 /林炯森大夫 |
||
|
4/18(W3) |
Bortezomib, melphalan, prednisone, and thalidomide for
relapsed multiple myeloma Blood. 2007;109:2767-2772)
|
|
||
|
4/20(W5) |
Sunitinib:
From Rational Design to Clinical Efficacy VOL25 No7 |
|
||
|
4/25(W3) |
Imatinib
combined with induction or consolidation chemotherapy in patients with de novo Ph
chromosome(+) ALL: results of the GRAAPH-2003 study (Blood. 2007;109:1408-1413) |
R2 陳席軒/林煥超大夫 |
||
|
4/27(W5) |
Mortality conference |
R4鄭弘毅/謝瑞坤主任 |